Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Drucker

Showing results (531-540 of 549) with videos related to

Pageof 55
Sort By:
Biorxiv : the Preprint Server for Biology|January 30, 2023
Liver Fibroblast Growth Factor 21 (FGF21) is Required for the Full Anorectic Effect of the Glucagon-Like Peptide-1 Receptor Agonist Liraglutide in Male Mice fed High Carbohydrate DietsThao D V Le, Payam Fathi, Amanda B Watters, et al.
Nature|February 1, 2019
Gut intraepithelial T cells calibrate metabolism and accelerate cardiovascular diseaseShun He, Florian Kahles, Sara Rattik, et al.
Nature Medicine|November 1, 2011
Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cellsHelga Ellingsgaard, Irina Hauselmann, Beat Schuler, et al.
Molecular Metabolism|April 27, 2024
Intra-islet glucagon signalling regulates beta-cell connectivity, first-phase insulin secretion and glucose homoeostasisK Suba, Y Patel, A Martin-Alonso, et al.
Nature Chemical Biology|July 15, 2009
A new glucagon and GLP-1 co-agonist eliminates obesity in rodentsJonathan W Day, Nickki Ottaway, James T Patterson, et al.
Molecular Metabolism|April 8, 2023
Fibroblast growth factor-21 is required for weight loss induced by the glucagon-like peptide-1 receptor agonist liraglutide in male mice fed high carbohydrate dietsThao D V Le, Payam Fathi, Amanda B Watters, et al.
Molecular Metabolism|February 7, 2026
Ectopic, hepatic GLP-1R agonism enhances the weight loss efficacy of GLP-1 analoguesJonathan D Douros, Megan Capozzi, Aaron Novikoff, et al.
Kidney International|December 9, 2023
Glucagon-like peptide-1 receptor signaling modifies the extent of diabetic kidney disease through dampening the receptor for advanced glycation end products-induced inflammationKarly C Sourris, Yi Ding, Scott S Maxwell, et al.
Cell Metabolism|November 1, 2019
Proteomics-Based Comparative Mapping of the Secretomes of Human Brown and White Adipocytes Reveals EPDR1 as a Novel BatokineAtul S Deshmukh, Lone Peijs, Jacqueline L Beaudry, et al.
Molecular Metabolism|November 27, 2019
Glucagon-like peptide 1 (GLP-1)T D Müller, B Finan, S R Bloom, et al.
Pageof 55

Showing results (531-540 of 549) with videos related to

Sort By:
Pageof 55
Biorxiv : the Preprint Server for Biology|January 30, 2023
Liver Fibroblast Growth Factor 21 (FGF21) is Required for the Full Anorectic Effect of the Glucagon-Like Peptide-1 Receptor Agonist Liraglutide in Male Mice fed High Carbohydrate DietsThao D V Le, Payam Fathi, Amanda B Watters, et al.
Nature|February 1, 2019
Gut intraepithelial T cells calibrate metabolism and accelerate cardiovascular diseaseShun He, Florian Kahles, Sara Rattik, et al.
Nature Medicine|November 1, 2011
Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cellsHelga Ellingsgaard, Irina Hauselmann, Beat Schuler, et al.
Molecular Metabolism|April 27, 2024
Intra-islet glucagon signalling regulates beta-cell connectivity, first-phase insulin secretion and glucose homoeostasisK Suba, Y Patel, A Martin-Alonso, et al.
Nature Chemical Biology|July 15, 2009
A new glucagon and GLP-1 co-agonist eliminates obesity in rodentsJonathan W Day, Nickki Ottaway, James T Patterson, et al.
Molecular Metabolism|April 8, 2023
Fibroblast growth factor-21 is required for weight loss induced by the glucagon-like peptide-1 receptor agonist liraglutide in male mice fed high carbohydrate dietsThao D V Le, Payam Fathi, Amanda B Watters, et al.
Molecular Metabolism|February 7, 2026
Ectopic, hepatic GLP-1R agonism enhances the weight loss efficacy of GLP-1 analoguesJonathan D Douros, Megan Capozzi, Aaron Novikoff, et al.
Kidney International|December 9, 2023
Glucagon-like peptide-1 receptor signaling modifies the extent of diabetic kidney disease through dampening the receptor for advanced glycation end products-induced inflammationKarly C Sourris, Yi Ding, Scott S Maxwell, et al.
Cell Metabolism|November 1, 2019
Proteomics-Based Comparative Mapping of the Secretomes of Human Brown and White Adipocytes Reveals EPDR1 as a Novel BatokineAtul S Deshmukh, Lone Peijs, Jacqueline L Beaudry, et al.
Molecular Metabolism|November 27, 2019
Glucagon-like peptide 1 (GLP-1)T D Müller, B Finan, S R Bloom, et al.
Pageof 55